
FDA Expedites Pancreatic Cancer Drug Development
The FDA is fast-tracking the development of a promising new drug for pancreatic cancer known as daraxonrasib. This medication aims to block cancer signals associated with the RAS gene. It has completed an early-stage clinical trial, evaluating its safety and effectiveness for humans. Daraxonrasib was tested on 168 patients diagnosed with advanced pancreatic cancer who […]








